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ABSTRACT
Background: Garcinol is a polyisoprenylated benzophenone derived 
from rinds of fruit of Garcinia species namely Garciniaindica (common 
name ‘Kokum’) and Garcinia cambogia (common name ‘Gombogee’).
Garcinol is not stable and has poor bioavailability which can be 
improved by complexing garcinol with cyclodextrin (cyclodextrin-
garcinol complex). 
Objective: The objective of the present study was to investigate effect 
of cyclodextrin-garcinol complex (20 mg/kg/) on pressure overload- 
induced cardiotoxicity and cardiac hypertrophy by aortic stenosis in rats.
Methods: Male Wistar rats (250-300g) were divided into following 
four groups such as: control, sham, stenosis and cyclodextrin-garcinol 
complex. Daily body weights were recorded. Cyclodextrin-garcinol 
complex (20 mg/kg/day) in distilled water, was administered orally 
to rats daily for 18 days and then the animals underwent surgery 
with aortic binding, the treatment was continued up to 4-6 weeks. 
Haemodynamic changes and electrocardiogram (ECG) were recorded 
in anaesthetized rats.
Results: Pressure overload induced by arotic stenosis in rat resulted 
in significant myocardial hypertrophy and decreased endogenous 
antioxidants when compared with the control and sham group 
animals. Cyclodextrin-garcinol complex (20 mg/kg) showed significant 
cardioprotective activity by lowering the myocardial hypertrophy, 
level of lipid peroxidation (MDA content) as well as elevated the level 
of GSH. The results suggest pre-treatment of cyclodextrin-garcinol 
complex (20 mg/kg), may offer potential benefits in the management 
of cardiotoxicity and cardiac hypertrophy.
Conclusion: It is concluded that cyclodextrin-garcinol complex 
(20 mg/kg) protected the haemodynamics of stenosized heart of rats 
by reduction of lipid peroxidation and preservation of endogenous 
antioxidants in rat heart.
Keywords: Antioxidants, Cardiac hypertrophy, cyclodextrin-garcinol Complex (20 mg/kg), Aortic Stenosis.
INTRODUCTION
Increased cardiovascular mortality is a serious 
problem in modern societies. Minimizing the risk 
of cardiac disease and alleviating the complica-
tions of cardiovascular dysfunction are the main 
therapeutic aim in modern medicine.1 Our under-
standing of the mechanisms of pathophysiology of 
cardiovascular diseases has been gaining significant 
advances and a wealth of knowledge implicates 
sustained overload pressure and oxidative stress as 
a key causative agent. 
Small animal models are the most preferred tools 
for the study of chronic changes in the development 
of cardiac hypertrophy.2 Constriction of the ascend-
ing aorta is one of the most common and successful 
surgical models for creating pressure overload.3
Clinically occurrence of chronic pressure over-
load is a recurrent that leads to left ventricular 
hypertrophy (LVH). Initially, LVH was considered 
to be a compensatory mechanism that allows the 
generation of the required cardiac output and 
normalization of wall mechanical stress.4 Therefore, 
aortic stenosis-induced LVH and persistence 
systemic hypertension can become maladaptive 
and herald the onset of heart failure.5 In rats, grad-
ual aortic constriction for four to eight weeks has 
been reported to produce stable LV hypertrophy.6
The literature shows that in the heart, Ang II 
(Angiotensin-II) is playing a crucial factor in the 
development of cardiac fibrosis via collagen dispo-
sition and induction of fibroblast proliferation leads 
to progress of cardiac cell hypertrophy.7
It is reported that in vitro acute release of Ang 
II within 10 min and the expression of AGT gene 
(Angiotensin) after 6 h from cardiomyocytes is 
induced by the mechanical stretch.8 It also showed 
that Ang II acts as an initial mediator of the 
stretchinduced hypertrophic response. 
Angiotensin II acts via AT1 receptorIfor induc-
ing cardiac hypertrophy.Which is associated with 
increased expression of many immediate-early 
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genes (c-fos, c-jun, junB, Egr-1, and c-myc) and 
fetal marker genes of cardiac hypertrophy (ANF, 
skeletal α-actin, β-MHC) conferring a pathological 
phenotype.9,10
Additional evidence suggests that phosphory-
lated Akt/glycogen synthase kinase 3β (GSK3β), 
extracellular signal-regulated kinases 1 or 2 
(ERK1/2) and GATA binding protein 4 (GATA4) 
pathways play important roles in the process of 
cardiac hypertrophy and ventricular remodeling 
induced by pressure overload.11,12 All these alter-
ations lead to a worsening of cardiac function, 
associated with diminished contractility. 
The literature shows that chalcones having 
antioxidant, anti-inflammatory and ACE inhibitor 
property can reverse the pressure overload induced 
hypertrophy produced by arotic stenosis, patho-
genic conditions and sedentary life style. Garcinol 
is a polyisoprenylated benzophenone derived rinds 
fruit of Garcinia species namely Garciniaindica 
(common name ‘Kokum’) and Garcinia cambogia 
(common name ‘Gombogee’). It is a potent antioxi-
dant has a limitation of poor stability and bioavail-
ability.13 There are several methods to improve 
these limitations and complexation is one of them. 
Literature shows that cyclodextrin is a (α-1, 
4)-linked α-D-glucopyranose unit, which is able 
to form inclusion complexes with many drugs by 
taking up the drug molecule into the central cavity. 
No covalent bonds are formed or broken during 
complex formation. The complexed drug molecule 
remains in rapid equilibrium with free solvated and 
complexed forms in the solution. The complexation 
of garcinol with cyclodextrin is reported in litera-
ture. Cyclodextrin enhances the drug permeability 
by direct action on the biological membrane. It 
also increases the garcinol stability by restricting 
the drug solvent interaction. The overall result is 
increased bioavailability.14
The aim of present study was to investigate 
effect of cyclodextrin garcinol complex (cyclo-
dextrin-garcinol complex) on the pressure over 
induced cardiotoxicity and cardiac hypertrophy by 




The animals were housed under standard housing 
conditions of temperature (25ºC), relative humidity 
(60%) and photo period of 12 h dark/12 h light. 
Pellet diet (Chakan Oil Mills, Pune, India) and 
water were provided ad libitum. Male Wistar albino 
rats (250-300 g) were obtained from National 
Toxicological Centre (NTC) Pune. The Institutional 
Animal Ethics Committee (IAEC) ‘approved proto-
cols of animal experiments.
Chemicals and sample
Cyclodextrin-garcinol complex was obtained as 
gift sample from Indus Biotech Private Limited, 
Pune, Epinephrine hydrochloride, and malondial-
dehyde were purchased from Sigma Chemical Co., 
USA. Reduced glutathione (GSH), 5,5´-dithiobis 
(2-nitro benzoic acid) (DTNB) and thiobarbituric 
acid (TBA) were obtained from Hi media, India. All 
chemicals used were of analytical grade.
Procedure
Abdominal aortic coarctation was carried out 
as described by Cordelia et  al (2007).15 Rats were 
anesthetized with thiopental 25 mg/kg (i.p.). Under 
sterile conditions, the skin was cut open along the 
abdominal midline. Aortic constriction was created 
via a left thoracotomy by placing a ligature using 
sterilized silk suture of size 4-0 (purchased locally 
from Pune). After that a 40 mm long cannula of 
diameter 0.9 mm was placed longitudinally in 
the aorta & tied loosely with it. Then cannula was 
slowly removed, leaving an aortic lumen of 0.9 mm 
diameter. The skin was then closed by stitching. 
The presence of the ascending aortic constriction 
precludes left ventricular catheterization by a 
carotid approach in this model. 
Male Wistar rats (250-300g) were divided into 
following 4 groups. Group1 was control (pre-treated 
with vehicle i.e. cyclodextrin for 18 days then treat-
ment was continued up to 4-6 weeks). Group 2 was 
Sham (pre-treated with vehicle i.e. cyclodextrin for 
18 days & then under went surgery without aortic 
banding, treatment was continued up to 4-6 weeks). 
Group 3 was stenosis (pre-treated with vehicle i.e. 
cyclodextrin for 18 days & then underwent surgery 
with aortic banding, treatment was continued up 
to 4-6 weeks). Group 4 was cyclodextrin-garcinol 
complex (pre-treated with, cyclodextrin-garcinol 
complex 20 mg/kg/day for 18 days & then under-
went surgery with aortic banding, treatment was 
continued up to 4-6 weeks). Daily body weights 
were recorded .Cyclodextrin-garcinol complex 
(20 mg/kg/day) in distilled water was administered 
orally to group 4 rats daily for 18 days then treat-
ment was continued up to 4-6 weeks. On the basis 
of previous pilot study the dose was selected. The 
literature showed that the therapeutic potential 
of the cyclodextrin-garcinol complex at a dose of 
20 mg/kg is comparable to that of administration of 
100 mg/kg (p.o.) of garcinol.16 It confirms that the 
chemically cyclodextrin-garcinol complex increases 
its therapeutic index by making it more efficacious. 
Moreover, this activity of cyclodextrin-garcinol 
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complex was achieved without any mortality of the 
animals indicating elimination of toxicity. 
The rats were anaesthetized by anesthetic ether. 
The ECG, heart rate and blood pressure were 
recorded using 8 channels Power Lab System (AD 
Instruments Pvt. Ltd., Unit 13, 18-22 Lexington 
Drive, Bella Vista NSW 2153, Australia).The 
animals were sacrificed with overdose of thiopen-
tal. Randomly hearts from animals were selected 
for tissue parameter measurement. The heart of 
each animal was cut in to small pieces, placed in 
chilled 0.25M sucrose solution and blotted on a 
filter paper. The tissues were homogenized in 10% 
chilled Tris hydrochloride buffer (10mM, pH 7.4) 
by tissue homogenizer (Remi Motors, Mumbai, 
India) and centrifuged at 7500 rpm for 15 minutes 
at 0ºC using Eppendorf 5810-R high speed cooling 
centrifuge. The clear supernatant was used for the 
measurement of GSH and MDA content.
Tissue parameters
Lipid peroxidation assay (MDA content)
Lipid peroxidation was evaluated by the produc-
tion of thiobarbituric acid-reactive substances 
(TBARS).17 To2.0 ml of the tissue homogenate 
(supernatant) was added to 2.0 ml of freshly 
prepared 10% w/v trichloroacetic acid (TCA). The 
mixture was allowed to stand for 15 minutes in an 
ice bath, followed by centrifugation at 2500 rpm for 
10 minutes at 0°C. Then 2.0 ml of freshly prepared 
0.67%w/v thiobarbituric acid was mixed with 2.0 ml 
of clear supernatant solution. The resulting solution 
was heated in boiling water bath for 10 minutes. It 
was immediately placed for 5 minutes in ice bath 
to cool the solution. The absorbance of colour 
developed was measured against reagent blank by 
UV/VIS spectrophotometer (JASCO-V-530, Japan) 
at 532 nm using 1, 1, 3, 3-tetraethoxypropane as a 
standard. 
Measurement of GSH
GSH was estimated by method of Moron 
et  al(1979).18 Firstly, 1.0 ml of tissue homogenate 
(supernatant) and 1 ml of 20% trichloroacetic acid 
(TCA) were mixed. It was centrifuged at 2500 rpm 
for 15 minutes at 0°C. After that to 25 ml of super-
natant, 2 ml of 5, 5´-dithiobis (2-nitro benzoic acid) 
(0.6M) reagent was added. The final volume was 
made up to 3 ml with phosphate buffer (pH 8.0). 
The colour developed was read at 412 nm against 
reagent blank. The amount of reduced glutathione 
was expressed as µg of GSH /gm of protein.
Determination of organ weight ratio
Body weight was recorded before sacrifice of 
animal. Heart weight was recorded after keeping 
the heart in cold saline and squeezing out the blood 
followed by drying on tissue paper. The weight of 
left ventricle was recorded. The left ventricular 
weight/body weight ratio was calculated.
Statistical analysis
The statistical analysis was performed by ‘Graph pad 
prism’ software. All values were expressed as mean 
± SEM. One way ANOVA was applied to test the 
significance of biochemical data of different groups 
and multiple comparisons were determined by the 
Bonferroni Post hoc test. P < 0.05 was considered 
statistically significant.
RESULTS
Effect of cyclodextrin-garcinol complex 
on Systolic BP and Diastolic BP (mmHg) in 
male Wistar rats
The Systolic BP (SBP) was significantly (p<0.01) 
reduced in the stenosis group compared with 
normal group or sham. The diastolic BP (DBP) 
was significantly (p<0.01) reduced in the stenosis 
group compared with normal group and Sham. 
Pretreatment for 18 days and post stenosis treat-
ment for 28 days with cyclodextrin-garcinol 
complex (20 mg/kg) resulted in significant (p<0.05) 
decrease in systolic where as non- significant 
decrease in diastolic BP was non-significant in rats 
(Table 1).
Table 1  Effect of cyclodextrin-garcinol complex on myocardial SBP and DBP
Enzyme Control group Sham group Stenosis group
Cyclodextrin-garcinol 
complex (20 mg/kg) group
Systolic BP (mmHg) 86.36 ± 2.2 81.75 ± 2.6ns 115.72 ± 6.3 ## 95.612 ± 2.2*
Diastolic BP
(mmHg)
74.31 ± 2.47 64.80 ± 6.48ns 94.03 ± 3.48 ## 79.93 ± 3.48ns1
SBP- Systolic blood pressure, DBP- Diastolic blood pressure
(n = 8), data are mean (SEM)]
ns- non significantas compared with control group
## p<0.01 significant as compared with control and sham group,
*p <0.05 significant as compared with stenosis group. 
 ## p <0.01 significant as compared with control and sham group,
ns1- 
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Table 5  Effect of cyclodextrin-garcinol complex on heart to body weight ratio of rats
Ratio Control group Sham group Stenosis group
Cyclodextrin-garcinol 
complex (20 mg/kg) group
Heart to body 
weight mg/g
3.135 ± 0.078 2.985 ± 0.0769 ns 4.085 ± 0.037### 3.42 ± 0.0486***
[(n = 8), data are mean (SEM)]
ns non significant compared with control group
### p<0.001 significant as compared with control and Sham group, 
*** p<0.001 significant as compared with Stenosis group.









(20 mg/kg) group (msec)
QT -0.0012± 0.00067 -0.0011± 0.0009ns 0.0187±0.001 ### 0.0067±0.0017***
ST -0.0011 ± 0.002 -0.0024± 0.002ns 0.014 ±0.0017### 0.006±0.002 *
[(n = 8), data are mean (SEM)]
ns non significant compared with control group
### p<0.001 significant as compared with control and sham group,
*** p<0.001 significant as compared with stenosis group. 
### p<0.001 significant as compared with control and sham group,
* p<0.05 significant as compared with stenosis group. 
Table 3  Effect of cyclodextrin-garcinol complex on heart rate of rats
Ratio Control group Sham group Stenosis group
Cyclodextrin-garcinol 
complex (20 mg/kg) group
Heart rate
(beats/min)
4.583 ± 7.413 -13.05 ± 12.8ns -88.79 ± 12.31 ### -45.64 ± 4.673*
[(n = 8), data are mean (SEM)]
ns non significant compared with control group
### p<0.001 significant as compared with control and sham group, 
* p<0.05significant as compared with stenosis group.









complex (20 mg/kg) group
Left ventricular to 
body weight mg/g
1.516 ± 0.023 1.569 ± 0.0305 ns  1.968 ± 0.0324 ### 1.711 ± 0.0312***
[(n = 8), data are mean (SEM)]
ns non significant compared with control group
### p<0.001significant as compared with control and sham group,
*** p<0.001 significant as compared with stenosis group.
Table 2  Effect of cyclodextrin-garcinol complex on myocardial MABP
Enzyme Control group Sham group Stenosis group
Cyclodextrin-garcinol 
complex (20 mg/kg) group
MABP (mmHg) 77.994 ± 4.58 70.45 ± 4.58ns  101.40 ± 4.06## 91.128 ± 3.04ns1
MABP- Mean arterial blood pressure
(n = 8), data are mean (SEM)]
ns- non significant as compared with control group
## p<0.01 significant as compared with control and sham group, 
non significant as compared with stenosis group.
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Effect of garcinol complex on 
MABP (mmHg) in male Wistar rats 
The mean arterial blood pressure (MABP) was 
significantly (p<0.01) reduced in the stenosis group 
compared with normal group or sham). Pretreatment 
for 18 days and post stenosis treatment for 
28 days with garcinol complex (20 mg/kg) resulted in 
non-significant increase in the MABP as compared 
with stenosis group in male wistar rats (Table 2).
Effect of cyclodextrin-garcinol complex 
(20mg/kg) on heart rate of male Wistar rats 
Heart rate was significantly (p<0.001) higher in the 
stenosis group compared with the control group 
and sham group Pretreatment for 18 days and 
post stenosis treatment for 28 days with cyclodex-
trin-garcinol complex (20 mg/kg) resulted insignif-
icant (p<0.05) reduction in heart rate as compared 
with stenosis group (Table 3). 
Effect of cyclodextrin-garcinol complex on 
electrocardiograph of rats
The mean (SEM) QT interval was significantly 
(p<0.001) higher in the stenosis group compared 
with the control group, respectively. The ST inter-
val was also significantly (p<0.001) higher in the 
stenosis group. Pretreatment for 18 days and post 
stenosis treatment for 28 days with cyclodex-
trin-garcinol complex (20 mg/kg) lowered QT and 
ST intervals significantly (p<0.05), compared with 
the stenosis group (Table 4 and Figure 2).
Effect of cyclodextrin-garcinol complex 
(20 mg/kg) on heart weight/body weight 
ratio 
Heart to body weight ratio was significantly 
(p<0.001) higher in the stenosis group compared 
with the control group and Sham group. 
Pretreatment for 18 days and post stenosis treatment 
for 28 days with cyclodextrin-garcinol complex 
(20 mg/kg) resulted in significant (p<0.001) reduc-
tion in the ratio of heart weight/body weight as 
compared with stenosis group (Table 5).
Effect of cyclodextrin-garcinol complex 
(20mg/kg) on Left ventricular weight/Body 
weight ratio 
Left ventricular to body weight ratio was significantly 
(p<0.001) higher in the stenosis group compared 
with the control group and sham group Pretreatment 
for 18 days and post stenosis treatment for 28 days 
with cyclodextrin-garcinol complex  (20  mg/kg) 
resulted insignificant (p<0.001) reduction in the 
ratio of left ventricular weight/body weight of the 
rats compared to stenosis group (Table 6).
Effect of cyclodextrin-garcinol complex on 
myocardial MDA levels
Myocardial MDA concentration was signifi-
cantly (p<0.001) higher in the stenosis group 
compared with the control group and sham group 
Pretreatment for 18 days and post stenosis treatment 
for 28 days with cyclodextrin-garcinol complex 
(20 mg/kg) resulted in lowering MDA concentration 
significantly (p<0.01) in the  cyclodextrin-garcinol 
complex (20 mg/kg) group compared with the 
stenosis group (Table 7).
Table 7  Effect of cyclodextrin-garcinol complex on myocardial MDA and GSH levels
Enzyme Control group Sham group Stenosis group
Cyclodextrin-garcinol 
complex (20 mg/kg) group
MDA, nM/mg 
protein
2.729± 0.1250 3.399 ± 0.2121ns 4.546± 0.1797### 3.458 ± 0.9755**
GSH, μg/mg protein 30.39 ± 1.605 26.09 ± 0.6497ns 18.73 ± 0.7187 ### 25.53 ± 1.700 *
MDA- malondialdehyde, GSH- glutathione. 
[(n = 8), data are mean (SEM)]
ns non significant compared with control group
### p<0.001significant as compared with control and sham group, 
** p<0.01 significant as compared with stenosis group. 
### p<0.001 significant as compared with control and sham group.
*p<0.05 significant as compared with stenosis group,
Figure 1  Effect of Cyclodextrin-garcinol complex (20 mg/kg) on heart 
weight in rats in experimentally induced cardiac hypertrophy by 
rat aortic stenosis.
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Effect of cyclodextrin-garcinol complex on 
myocardial GSH levels
Myocardial GSH concentration was significantly 
(p<0.001) lower in the stenosis group compared 
with the control group. Pretreatment for 18 days 
and post stenosis treatment for 28 days with cyclo-
dextrin-garcinol complex (20 mg/kg) resulted 
in significantly (p<0.05) higher myocardial GSH 
concentration in the cyclodextrin-garcinol complex 
(20 mg/kg) group compared with stenosis group 
(Table 7).
DISCUSSION
Haemodynamic, sustained pressure overload will 
override these adaptive mechanisms, leading to 
cardiac hypertrophy, decreased contractile func-
tion, and the development of heart failure. The 
literature showed in vivo studies that, the molecular 
pathways involved in cardiac hypertrophy can be 
specifically by exposing rats to either biomechan-
ical stress through transaortic constriction of the 
aorta. Although left ventricular hypertrophy is 
the most important compensation mechanism in 
chronic pressure overload, it has frequently been 
associated with heart failure and death.19 It occurs 
because the hypertrophied myocardium presents 
structural changes that lead to cardiac remodeling, 
such as a disproportional increase in the myocytes 
component compared to vascular component. 
One of the consequences is an imbalance between 
oxygen supply and consumption, which causes 
myocytes necrosis, apoptosis, and abnormal colla-
gen accumulation. Fibrosis also occurs as a direct 
consequence of activation of the  renin-angiotensin 
system in the myocardium.20 The stimuli for devel-
oping cardiac remodeling also include mechanical 
and biochemical factors which, acting on receptors, 
ionic channels, and integrin present in the sarco-
lemma membrane.21 trigger cytosolic biochemical 
signals provoking increased protein synthesis and 
changes in gene expression.22 All these alterations 
lead to a worsening of cardiac function, associated 
with diminished contractility.
In the present investigation the cardiac hypertro-
phy was confirmed by the heart weight /body weight 
ratio and left ventricular weight /body weight ratio 
in rats. In the stenosis group significant increase 
in both the ratios was observed. Pretreatment for 
18 days and post stenosis treatment for 28 days, 
resulted in the significant reduction in both ratios. 
Result thus indicated that complex (20mg/kg) 
possessed anti-hypertrophic effect. Aortic steno-
sized rats showed decrease in heart rate.23 These 
results were consistent with the earlier studies where 
it was hypothesized that aortic stenosis condition 
induced reactive oxygen species formation causes 
disturbance in calcium homeostasis.24 This could 
lead to a reduction in heart rate because decrease in 
intracellular calcium reduced excitability of pace-
maker cells in the sino atrial node and other cells in 
the cardiac conduction system. 
In recent years, electrical remodeling has emerged 
as an important pathophysiological mechanism in 
the development of mechanical dysfunction, pump 
failure and sudden death.When detected by electro-
cardiography, cardiac hypertrophy and heart failure 
are commonly associated with the development of 
QT and ST interval prolongation or dispersion and 
life threatening arrhythmias.25,26 Clinical studies 
suggest that 50% of sudden deaths associated with 
heart failure are attributable to ventricular tachy-
cardia or fibrillation, the other half being coupled 
to bradyarrhythmias or electromechanical dissoci-
ation.27 The electrocardiographic parameter from 
Figure 2  Effect of cyclodextrin-garcinol complex (20 mg/kg) on QT and 
ST interval of male Wistar rats in experimentally induced cardiac 
hypertrophy by rat aortic stenosis
1)  ECG of rat from Sham group on 44thday shows the normal response
2)  ECG of rat from aortic stenosis group on 44thday shows the prolongation 
in QT and ST segment of the ECG.
3)  ECG of rat from cyclodextrin-garcinol group on 44thday shows the 
reversal of the prolongation in QT and ST segment of the ECG.
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this study indicated that aortic stenosis significantly 
prolonged QT and ST intervals as compared to sham 
group, while treatment of cyclodextrin-garcinol 
complex resulted in significant reduction of the QT 
and ST interval prolongation.
In aortic stenosized rats significant increase in 
MDA content in cardiac tissues as well as highly 
significant reduction in cardiac tissue levels of 
protective biological antioxidant enzymes like GSH 
were compared to that of the sham group indicating 
oxidative stress. These results correlate with previ-
ous studies which have demonstrated the involve-
ment of oxidative stress and lipid peroxidation in 
aortic stenosis induced cardiac hypertrophy.28 The 
treatment with cyclodextrin-garcinol complex 
(20 mg/kg) significantly increased the GSH levels 
and decrease the MDA level, that producing a 
cardioprotective effect. Haemodynamic changes 
revealed that the aortic stenosis group showed 
significant increase in MABP, systolic and diastolic 
BP, as compared with sham group. While treat-
ment of cyclodextrin-garcinol complex (20 mg/kg) 
showed non-significant decrease in the MABP, 
systolic blood pressure and diastolic blood pressure. 
CONCLUSION
It is concluded that cyclodextrin-garcinol complex 
(20 mg/kg) protected the haemodynamics of steno-
sized heart of rats, restoration of normal function 
of stenosized heart is reflected by minimal (non 
significant) response change in MABP, Systolic BP, 
and Diastolic BP. It offered significant protection 
against cardiotoxicity and cardiac hypertrophy as 
well as reduced myocardial injury by reduction of 
lipid peroxidation and preservation of endogenous 
antioxidants in rat heart.
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